IndustryCompany release

Fulgent Genetics Q3 revenue reaches $90.4M, company holds full-year guidance

🇺🇸 Fulgent Genetics, Inc. (FLGT) · Thu 05 Nov 2026

The US genetic testing company reported a narrower non-GAAP loss outlook for 2026 and projected year-end cash and investments of about $630 million.

Fulgent Genetics (NASDAQ: FLGT) reported results for the quarter ended 30 September 2026 on 5 November, posting revenue of $90.4 million. The company's headline for the release described the figure as about 8% higher.

The company recorded a GAAP loss of $13.2 million for the quarter. On a non-GAAP basis, the loss was $2.4 million.

Fulgent held its 2026 revenue guidance at $330 million to $340 million. It narrowed its expected full-year non-GAAP loss to a range of $46 million to $50 million.

The company also projected cash and investments of about $630 million at the end of 2026. The full release was not available for this report, so details on segment performance, test volumes and the drivers behind the figures are not covered here.

What it means for your team

  • Fulgent's unchanged revenue guidance of $330-340 million suggests no change to its full-year top-line expectations as of early November 2026.
  • Teams assessing Fulgent as a laboratory or testing partner can note the projected year-end cash and investments of about $630 million.
  • Segment-level detail was not available, so any assessment of specific test lines or services would require the full earnings release.

Company's press release (SEC filing): Fulgent Genetics, Inc. ↗

Article written by VigiEye from the official source (Fulgent Genetics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →